1
|
Chen W, Liu Q, Fu B, Liu K, Jiang W. Overexpression of GRIM-19 accelerates radiation-induced osteosarcoma cells apoptosis by p53 stabilization. Life Sci 2018; 208:232-238. [PMID: 30005830 DOI: 10.1016/j.lfs.2018.07.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Revised: 07/04/2018] [Accepted: 07/09/2018] [Indexed: 02/09/2023]
Abstract
AIMS Osteosarcoma is one of the most aggressive types of primary bone cancer that responds poorly to radiotherapy frequently. The gene associated with retinoid-interferon mortality (GRIM-19) is a tumor suppressor that mediates cell apoptosis in multiple cancer types. However, the role of GRIM-19 in osteosarcoma and the underlying mechanism remain unclear. This study was designed to investigate the role and the underlying mechanism of GRIM-19 in osteosarcoma progression. MATERIALS AND METHODS Osteosarcoma tissues and cell lines were utilized to analyze the expressions of GRIM-19 in osteosarcoma by qRT-PCR and Western blot. Methods containing flow cytometry, irradiation exposure, cells inoculation, plasmid transfection, and protein immunoprecipitation were used to investigate the underlying mechanisms of GRIM-19 in osteosarcoma progression. KEY FINDINGS GRIM-19 is downregulated in osteosarcoma tissues and cell lines. Exposure to radiation induces osteosarcoma cell apoptosis by upregulation of p53 both in U2OS (p53-wt) and exogenous p53-introduced MG-63 (p53-null) osteosarcoma cells. Overexpression of GRIM-19 accelerates radiation-induced osteosarcoma cells apoptosis by p53 stabilization ex vivo and in vivo. Mechanistically, forced expression of GRIM-19 diminishes the activity of E3 ubiquitin-protein ligase mouse double minute 2 homolog (MDM2), a specific p53 protease, results in the accumulation of p53 and activation of p53-mediated apoptosis. SIGNIFICANCE GRIM-19 was proved to modulate radiation-induced osteosarcoma cells apoptosis in a p53 dependent manner by mediating MDM2 activity, which sheds light on the development of GRIM-19-based molecular target therapy on osteosarcoma.
Collapse
Affiliation(s)
- Wanhong Chen
- Medical Imaging Department, Huai'an Second People's Hospital and The Affiliated Huaian Hospital of Xuzhou Medical University, Huai'an, China
| | - Qingbai Liu
- Department of Orthopedics, Lianshui County People's Hospital, Huai'an, China
| | - Bin Fu
- Department of Orthopedics, Wujin People's Hospital, Changzhou, China
| | - Kai Liu
- Department of Radiology, Lianshui County People's Hospital, Huai'an, China.
| | - Wenchao Jiang
- Department of Orthopedics, Wujin People's Hospital, Changzhou, China.
| |
Collapse
|
2
|
Retinoid interferon-induced mortality19 (GRIM19) inhibits proliferation and invasion in rheumatoid arthritis fibroblast-like synoviocytes. Biomed Pharmacother 2018; 98:719-725. [DOI: 10.1016/j.biopha.2017.12.114] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2017] [Revised: 12/15/2017] [Accepted: 12/29/2017] [Indexed: 01/10/2023] Open
|
3
|
Ilelis F, do Amaral NS, Alves MR, da Costa AABA, Calsavara VF, Lordello L, De Brot L, Soares FA, Rodrigues IS, Rocha RM. Prognostic value of GRIM-19, NF-κB and IKK2 in patients with high-grade serous ovarian cancer. Pathol Res Pract 2017; 214:187-194. [PMID: 29254797 DOI: 10.1016/j.prp.2017.12.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Revised: 11/21/2017] [Accepted: 12/04/2017] [Indexed: 12/16/2022]
Abstract
AIMS High grade serous carcinoma (HGSC) is an aggressive tumour, and most patients relapse after treatment, acquiring resistance to platinum-based chemotherapy. One of the resistance mechanisms proposed is apoptosis evasion triggered by drug-related cytotoxic effect in the cell. In this context, this study aims to evaluate the protein expression of GRIM-19, NF-κB and IKK2, their association with chemotherapy response and to determine their prognostic values in HGSC. METHODS GRIM-19, NF-κB and IKK2 expression was evaluated by immunohistochemistry (IHC) in 71 patients with HGSC selected between 2003 and 2013, whose underwent primary debulking surgery with complete cytoreduction. Protein expression was analyzed in relation to platinum response groups, tumour progression, clinicopathological data and survival. RESULTS Positive IKK2 expression was related to resistance (p = 0.011), shorter disease-free survival (p = 0.001) and overall survival (p = 0.026) and was also a risk factor for relapse (p = 0.002) and death (p = 0.032). The association between IKK2 and NF-κB positivity predicted a subgroup with shorter overall survival (p = 0.004), disease-free survival (p = 0.003) and resistance to platinum-based chemotherapy (p = 0.036). NF-κB positivity was associated with worse overall survival (p = 0.005) and disease-free survival (p = 0.027) and was a positive predictor for relapse (p = 0.032) and death (p = 0.008). Higher expression of GRIM-19 was associated with higher disease-free survival (p = 0.039) and was a negative predictor for relapse (p = 0.046). CONCLUSIONS GRIM-19 is a potential predictor of prognosis and disease recurrence in HGSC. IKK2 and NF-κB are related to poor prognosis and are potential predictors of response to platinum-based chemotherapy in HGSC. IHC analyses of GRIM19, IKK2 and NF-κB may be important in the attempt to provide prognostic values for relapse and response to treatment in patients with HGSC.
Collapse
Affiliation(s)
- Felipe Ilelis
- Laboratory of Molecular Morphology, Department of Investigative Pathology,A.C.Camargo Cancer Center, Brazil.
| | - Nayra Soares do Amaral
- Laboratory of Molecular Morphology, Department of Investigative Pathology,A.C.Camargo Cancer Center, Brazil
| | - Mariana Rezende Alves
- Laboratory of Molecular Morphology, Department of Investigative Pathology,A.C.Camargo Cancer Center, Brazil
| | | | | | | | - Louise De Brot
- Department of Anatomic Pathology,A.C.Camargo Cancer Center, Brazil
| | | | - Iara Sant'Ana Rodrigues
- Laboratory of Molecular Morphology, Department of Investigative Pathology,A.C.Camargo Cancer Center, Brazil
| | - Rafael Malagoli Rocha
- Laboratory of Molecular Gynaecology, Department of Gynaecology, Federal University of São Paulo, Brazil
| |
Collapse
|
4
|
GRIM-19 represses the proliferation and invasion of cutaneous squamous cell carcinoma cells associated with downregulation of STAT3 signaling. Biomed Pharmacother 2017; 95:1169-1176. [DOI: 10.1016/j.biopha.2017.09.055] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2017] [Revised: 08/28/2017] [Accepted: 09/12/2017] [Indexed: 12/28/2022] Open
|
5
|
Pang L, Xia Y, Wang D, Meng X. Antitumor activity of iNGR-GRIM-19 in colorectal cancer. Jpn J Clin Oncol 2017; 47:795-808. [PMID: 28903530 DOI: 10.1093/jjco/hyx090] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Accepted: 06/23/2017] [Indexed: 12/27/2022] Open
Affiliation(s)
- Li Pang
- Department of Emergency, The First Hospital of Jilin University
| | - Yan Xia
- Department of Gastroenterology, The First Hospital of Jilin University, Changchun, Jilin130021, China
| | - Dawei Wang
- Department of Emergency, The First Hospital of Jilin University
| | - Xiangwei Meng
- Department of Gastroenterology, The First Hospital of Jilin University, Changchun, Jilin130021, China
| |
Collapse
|
6
|
Zhou Y, Xu F, Tao F, Feng D, Ling B, Qian L, Yang X, Wang Q, Wang H, Zhao W, Cheng Y, Shan G, Kalvakolanu DV, Xiao W. GRIM-19 Restores Cervical Cancer Cell Senescence by Repressing hTERT Transcription. J Interferon Cytokine Res 2016; 36:506-15. [PMID: 27142689 DOI: 10.1089/jir.2015.0125] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
High telomerase activity promotes tumor growth by stabilizing damaged chromosomes and their mitotic replication. Overactivation of telomerase activity has been reported in cervical cancer, a malignancy caused by high-risk human papillomaviruses (HR-HPVs). The HR-HPV E6 can activate hTERT promoter by interacting with E6AP or other binding proteins and by stabilizing the interaction between hTERT and E6AP. GRIM-19 is a novel tumor suppressor that affects multiple targets in a cell to regulate growth. We have previously reported the interaction of GRIM-19 with 18E6 and E6AP to disrupt the E6/E6AP complex and increase the autoubiquitination of E6AP. In this study, we characterized the interaction of GRIM-19 with 16E6 (an oncoprotein produced by HPV16) and identified the binding sites that mediate this interaction. We also found that GRIM-19 expression in cervical cancer cells could inhibit telomerase activity by inhibiting the transactivation of the hTERT promoter by E6, thereby promoting cervical cancer cell senescence. Moreover, we identified a negative correlation between GRIM-19 and hTERT expression in cervical cancer tissues. Suppression of GRIM-19 and induction of hTERT levels were associated with lymph node metastasis, advanced clinical stage, and poor prognosis. This study identified another important novel antitumor molecular link associated with GRIM-19 in the tumorigenesis.
Collapse
Affiliation(s)
- Ying Zhou
- 1 Department of Obstetrics and Gynecology, Anhui Provincial Hospital Affiliated to Anhui Medical University , Hefei, China
| | - Fei Xu
- 1 Department of Obstetrics and Gynecology, Anhui Provincial Hospital Affiliated to Anhui Medical University , Hefei, China
| | - Feng Tao
- 1 Department of Obstetrics and Gynecology, Anhui Provincial Hospital Affiliated to Anhui Medical University , Hefei, China
| | - Dingqing Feng
- 1 Department of Obstetrics and Gynecology, Anhui Provincial Hospital Affiliated to Anhui Medical University , Hefei, China
| | - Bin Ling
- 1 Department of Obstetrics and Gynecology, Anhui Provincial Hospital Affiliated to Anhui Medical University , Hefei, China
| | - Lili Qian
- 1 Department of Obstetrics and Gynecology, Anhui Provincial Hospital Affiliated to Anhui Medical University , Hefei, China
| | - Xia Yang
- 1 Department of Obstetrics and Gynecology, Anhui Provincial Hospital Affiliated to Anhui Medical University , Hefei, China
| | - Qingyuan Wang
- 1 Department of Obstetrics and Gynecology, Anhui Provincial Hospital Affiliated to Anhui Medical University , Hefei, China
| | - Huiyan Wang
- 1 Department of Obstetrics and Gynecology, Anhui Provincial Hospital Affiliated to Anhui Medical University , Hefei, China
| | - Weidong Zhao
- 1 Department of Obstetrics and Gynecology, Anhui Provincial Hospital Affiliated to Anhui Medical University , Hefei, China
| | - Yong Cheng
- 2 Department of Oncological Radiotherapy, Anhui Provincial Hospital Affiliated to Anhui Medical University , Hefei, China
| | - Ge Shan
- 3 Hefei National Laboratory for Physical Sciences, Microscale and School of Life Sciences, University of Science and Technology of China , Hefei, Anhui, China
| | - Dhan V Kalvakolanu
- 4 Department of Microbiology and Immunology, Greenebaum Cancer Center, University of Maryland School of Medicine , Baltimore, Maryland
| | - Weihua Xiao
- 3 Hefei National Laboratory for Physical Sciences, Microscale and School of Life Sciences, University of Science and Technology of China , Hefei, Anhui, China
| |
Collapse
|
7
|
Zhang W, Shao Y, Du Y, Geng W, Jiang T, Liu H, Zhang D. Additive effects of eukaryotic co‑expression plasmid carrying GRIM‑19 and LKB1 genes on breast cancer in vitro and in vivo. Mol Med Rep 2015; 12:7665-72. [PMID: 26458553 DOI: 10.3892/mmr.2015.4393] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Accepted: 08/19/2015] [Indexed: 11/06/2022] Open
Abstract
Gene associated with retinoid‑interferon‑induced mortality 19 (GRIM‑19) and the liver kinase B1 (LKB1) gene, two types of tumor suppressor gene, have been demonstrated to have important roles in breast carcinogenesis. The present study developed a dual expression plasmid that co‑expressed GRIM‑19 and LKB1, and evaluated the combined effects of the two genes against breast cancer in vitro and in vivo. Transfection with a plasmid for the simultaneous expression of GRIM‑19 and LKB1 (pGRIM19‑LKB1) into MCF‑7 breast cancer cells significantly inhibited the proliferation, colony formation, migration and invasion compared with the effects of transfection with either pGRIM‑19 or pLKB1 alone. Furthermore, transfection with pGRIM19‑LKB1 induced enhanced levels of apoptosis and cell cycle arrest at G0/G1 stage in MCF7 cells compared to the effects of pGRIM‑19 or pLKB1 alone. An in vivo experiment using an MCF‑7 xenograft tumor model demonstrated that intravenous injection of pGRIM19‑LKB1 had an enhanced effect on tumor growth inhibition compared to that of pGRIM‑19 or pLKB1 alone. In conclusion the findings of the present study suggested that transfection with eukaryotic plasmid for the simultaneous expression of GRIM‑19 and LKB1 more effectively suppressed the growth of breast cancer in vitro and in vivo, and may therefore have therapeutic potential for the treatment of human breast cancer.
Collapse
Affiliation(s)
- Wei Zhang
- Department of Cosmetology Plastic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Ying Shao
- Department of Cosmetology Plastic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Ye Du
- Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Wei Geng
- Department of Gastrointestinal Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Tong Jiang
- Department of Neurological Surgery, The Second Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Haipeng Liu
- Department of Cosmetology Plastic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Duo Zhang
- Department of Cosmetology Plastic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| |
Collapse
|